Literature DB >> 33673623

Quantitative Proteomics Reveals Changes Induced by TIMP-3 on Cell Membrane Composition and Novel Metalloprotease Substrates.

Anna Paola Carreca1, Veronica Maria Pravatà2,3, Danilo D'Apolito4,5, Simone Bonelli1, Matteo Calligaris1,6, Elisa Monaca7, Stephan A Müller3, Stefan F Lichtenthaler3,8,9, Simone Dario Scilabra1.   

Abstract

Ectodomain shedding is a key mechanism of several biological processes, including cell-communication. Disintegrin and metalloproteinases (ADAMs), together with the membrane-type matrix metalloproteinases, play a pivotal role in shedding transmembrane proteins. Aberrant shedding is associated to several pathological conditions, including arthritis. Tissue inhibitor of metalloproteases 3 (TIMP-3), an endogenous inhibitor of ADAMs and matrix metalloproteases (MMPs), has been proven to be beneficial in such diseases. Thus, strategies to increase TIMP-3 bioavailability in the tissue have been sought for development of therapeutics. Nevertheless, high levels of TIMP-3 may lead to mechanism-based side-effects, as its overall effects on cell behavior are still unknown. In this study, we used a high-resolution mass-spectrometry-based workflow to analyze alterations induced by sustained expression of TIMP-3 in the cell surfaceome. In agreement with its multifunctional properties, TIMP-3 induced changes on the protein composition of the cell surface. We found that TIMP-3 had differential effects on metalloproteinase substrates, with several that accumulated in TIMP-3-overexpressing cells. In addition, our study identified potentially novel ADAM substrates, including ADAM15, whose levels at the cell surface are regulated by the inhibitor. In conclusion, our study reveals that high levels of TIMP-3 induce modifications in the cell surfaceome and identifies molecular pathways that can be deregulated via TIMP-3-based therapies.

Entities:  

Keywords:  ectodomain shedding; metalloproteinases; proteomics; tissue inhibitor of metalloproteases 3 (TIMP-3)

Mesh:

Substances:

Year:  2021        PMID: 33673623      PMCID: PMC7957584          DOI: 10.3390/ijms22052392

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  59 in total

Review 1.  Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.

Authors:  Hung-En Hsia; Johanna Tüshaus; Tobias Brummer; Yuanpeng Zheng; Simone D Scilabra; Stefan F Lichtenthaler
Journal:  Cell Mol Life Sci       Date:  2019-06-24       Impact factor: 9.261

2.  Human ROBO1 is cleaved by metalloproteinases and gamma-secretase and migrates to the nucleus in cancer cells.

Authors:  Motoaki Seki; Akira Watanabe; Satoshi Enomoto; Takeshi Kawamura; Hirotaka Ito; Tatsuhiko Kodama; Takao Hamakubo; Hiroyuki Aburatani
Journal:  FEBS Lett       Date:  2010-05-13       Impact factor: 4.124

Review 3.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity.

Authors:  Keith Brew; Hideaki Nagase
Journal:  Biochim Biophys Acta       Date:  2010-01-15

Review 4.  Proteolytic ectodomain shedding of membrane proteins in mammals-hardware, concepts, and recent developments.

Authors:  Stefan F Lichtenthaler; Marius K Lemberg; Regina Fluhrer
Journal:  EMBO J       Date:  2018-07-05       Impact factor: 11.598

5.  Highly enhanced expression of the disintegrin metalloproteinase MDC15 (metargidin) in rheumatoid synovial tissue.

Authors:  B B Böhm; T Aigner; C P Blobel; J R Kalden; H Burkhardt
Journal:  Arthritis Rheum       Date:  2001-09

6.  TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells.

Authors:  M C Anania; M Sensi; E Radaelli; C Miranda; M G Vizioli; S Pagliardini; E Favini; L Cleris; R Supino; F Formelli; M G Borrello; M A Pierotti; A Greco
Journal:  Oncogene       Date:  2011-02-21       Impact factor: 9.867

7.  Abnormal TNF activity in Timp3-/- mice leads to chronic hepatic inflammation and failure of liver regeneration.

Authors:  Fazilat F Mohammed; David S Smookler; Suzanne E M Taylor; Barbara Fingleton; Zamaneh Kassiri; Otto H Sanchez; Jane L English; Lynn M Matrisian; Billie Au; Wen-Chen Yeh; Rama Khokha
Journal:  Nat Genet       Date:  2004-08-22       Impact factor: 38.330

8.  Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha.

Authors:  Massimo Federici; Marta L Hribal; Rossella Menghini; Hiroko Kanno; Valentina Marchetti; Ottavia Porzio; Susan W Sunnarborg; Stefano Rizza; Matteo Serino; Veronica Cunsolo; Davide Lauro; Alessandro Mauriello; David S Smookler; Paolo Sbraccia; Giorgio Sesti; David C Lee; Rama Khokha; Domenico Accili; Renato Lauro
Journal:  J Clin Invest       Date:  2005-11-17       Impact factor: 14.808

9.  Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17.

Authors:  Neil Hoa; Shanli Tsui; Nikoo F Afifiyan; Amiya Sinha Hikim; Bin Li; Raymond S Douglas; Terry J Smith
Journal:  PLoS One       Date:  2012-04-10       Impact factor: 3.240

10.  TIMP3 is reduced in atherosclerotic plaques from subjects with type 2 diabetes and increased by SirT1.

Authors:  Marina Cardellini; Rossella Menghini; Eugenio Martelli; Viviana Casagrande; Arianna Marino; Stefano Rizza; Ottavia Porzio; Alessandro Mauriello; Anna Solini; Arnaldo Ippoliti; Renato Lauro; Franco Folli; Massimo Federici
Journal:  Diabetes       Date:  2009-07-06       Impact factor: 9.461

View more
  2 in total

Review 1.  Tissue Inhibitor of Metalloproteases 3 (TIMP-3): In Vivo Analysis Underpins Its Role as a Master Regulator of Ectodomain Shedding.

Authors:  Donatella Pia Spanò; Simone Dario Scilabra
Journal:  Membranes (Basel)       Date:  2022-02-11

2.  High-Resolution Secretome Analysis of Chemical Hypoxia Treated Cells Identifies Putative Biomarkers of Chondrosarcoma.

Authors:  Donatella Pia Spanò; Simone Bonelli; Matteo Calligaris; Anna Paola Carreca; Claudia Carcione; Giovanni Zito; Aldo Nicosia; Sergio Rizzo; Simone Dario Scilabra
Journal:  Proteomes       Date:  2022-07-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.